Sign in Create account
Sign in and upgrade to a paid plan to export futures history as CSV.
Sign in and upgrade to a paid plan to export corporate actions as CSV.

Gujarat Terce Laboratories Ltd

Healthcare · Pharmaceuticals & Biotechnology

BSE: 524314
₹36.09
▼ -0.16 (-0.44%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
73/100
Strong
Valuation
83/100
Undervalued
Momentum
31/100
Neutral

QVM read Quality at a discount Quality Strong, Valuation Undervalued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹28 Cr
PE (TTM)
13.2
Industry median 36.1 (152 companies)
Price to Book
2.9
PEG (TTM)
0.0
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
-56.4
Free Cash Flow
₹2 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-283.33%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-42.76%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-7.20%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-24.50%
as of Dec. 31, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-17.06%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.32
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.13
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
19.25
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
-1.98%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
-1.30%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
6.86%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
13.65%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
23.70%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
34.46%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • Yes Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.13)
  • Yes Return on equity is 15% or more (34.5%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

0 of 3 met
  • No 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Undervalued (below its own historical PE range))
  • Yes Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • No Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.4%
Low 36.0000 · High 36.8900
1W return
-4.3%
Low 35.5100 · High 41.8000
1M return
-8.1%
Low 35.2500 · High 42.1000
52W return
-56.4%
Low 35.1500 · High 43.9500
Lifetime High ₹82.7000 (Dec. 24, 2024)
Lifetime Low ₹4.7800 (July 13, 2009)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish0
Bearish6
5D
37.1
10D
37.7
20D
38.4
50D
41.4
100D
43.0
200D
40.4

Delivery and volume

Day avg. delivery
91.6%
Week avg. delivery
93.4%
Month avg. delivery
82.1%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

36.33
Pivot
First resistance36.65
Second resistance37.22
Third resistance37.54
First support35.76
Second support35.44
Third support34.87
Day RSI42.1
Day MFI22.5
Day MACD-1.17
Day MACD signal-1.14

Beta

1M1.82
3M1.08
1Y1.08
3Y0.11

Price change analysis

↓ -8.1%
Over 1 Month
LowHigh
35.2542.10
↓ -56.4%
Over 3 Months
LowHigh
35.1543.95
↓ -56.4%
Over 6 Months
LowHigh
35.1543.95
↓ -56.4%
Over 1 Year
LowHigh
35.1543.95
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 13.2 (own history: 13.6–160.5)
Undervalued (below its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹9 Cr
Net profit (June 30, 2026)
₹-0 Cr
Basic EPS (June 30, 2026)
₹-0.2300

Ranks #162 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter40.03%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings were unchanged at 40.03% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 100 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
26 Jun 2025 NELVIN GEORGE Bulk Sell 40,212 51.3700 BSE
15 Apr 2024 MABLE RAJESH Bulk Buy 73,000 52.4000 BSE
17 Nov 2023 DHANPAT M KOTHARI Bulk Buy 44,772 24.9200 BSE
15 Nov 2022 RISHABH NEGI Bulk Buy 75,000 18.6000 BSE
25 Aug 2022 GUPTA Bulk Sell 43,893 20.7800 BSE
16 Jun 2022 RADHIKA RASTOGI Bulk Buy 11 33.2500 BSE
16 Jun 2022 RADHIKA RASTOGI Bulk Sell 71,782 32.9200 BSE
15 Jun 2022 SATYA PRAKASH MITTAL HUF Bulk Sell 119,846 34.1000 BSE
3 Jun 2022 SATYA PRAKASH MITTAL HUF Bulk Buy 1,286 40.9000 BSE
3 Jun 2022 SATYA PRAKASH MITTAL HUF Bulk Sell 44,699 42.2100 BSE

All bulk and block deals →

Corporate Announcements

All 1 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
27 Sep 2026 Insider Trading / SAST Gujarat Terce Laboratories Ltd - 524314 - Closure of Trading Window

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • High Return on Equity (34.5%)
  • Low financial leverage (Debt/Equity 0.13)
  • Comfortable interest coverage (19.2x)

Weaknesses

  • Thin net profit margin (-2.0%)
  • Declining revenue YoY (-17.1%)
  • Declining profit YoY (-24.5%)

Opportunities

  • PEG below 1 (0.04) -- earnings growth outpacing its own valuation
  • PE below 15 (13.2) relative to a typical growth business

Threats

  • Down 56.4% over the past year

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Gujarat Terce Laboratories Ltd

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.